Back
#1
32.6%
#1
6.3%
Top 2%
5.9%
Top 0.2%
5.3%
Top 0.9%
5.3%
Top 0.4%
4.1%
Top 1%
3.2%
Top 0.5%
2.9%
Top 5%
2.9%
Top 16%
2.9%
Top 0.5%
2.0%
Top 14%
2.0%
Top 3%
1.6%
Top 2%
1.6%
Top 85%
1.6%
Top 1%
1.2%
Top 7%
1.0%
Top 0.7%
1.0%
Top 1%
1.0%
Top 3%
0.8%
Top 2%
0.8%
Top 7%
0.8%
Top 19%
0.8%
Top 8%
0.5%
Top 99%
0.5%
Early Fc-effector antibody signatures impact COVID-19 disease trajectory
2026-02-19
infectious diseases
Title + abstract only
View on medRxiv
Show abstract
Why do some individuals develop mild COVID-19 while others progress to severe disease remains a central challenge in SARS-CoV-2 immunology. In this study, we leveraged the BACO Cohort - a unique historical cohort of immunologically naive, hospitalized COVID-19 patients from the first pandemic wave - to investigate early immune determinants of clinical disease trajectories. Integrating bulk RNA-seq, Olink proteomics, and systems serology, we identified two fundamentally distinct immune trajectori...
Predicted journal destinations
1
Nature Communications
483 training papers
2
Cell
28 training papers
3
Frontiers in Immunology
140 training papers
4
Nature Medicine
88 training papers
5
JCI Insight
63 training papers
6
Cell Reports Medicine
49 training papers
7
iScience
74 training papers
8
Nature
58 training papers
9
The Journal of Infectious Diseases
137 training papers
10
eLife
262 training papers
11
Science Translational Medicine
40 training papers
12
Clinical Infectious Diseases
219 training papers
13
eBioMedicine
82 training papers
14
Journal of Clinical Investigation
50 training papers
15
Scientific Reports
701 training papers
16
PLOS Pathogens
35 training papers
17
Viruses
79 training papers
18
Science Immunology
15 training papers
19
The Journal of Immunology
19 training papers
20
mBio
34 training papers
21
Cell Reports
25 training papers
22
Science
46 training papers
23
Proceedings of the National Academy of Sciences
100 training papers
24
Genome Medicine
56 training papers
25
PLOS ONE
1737 training papers